30 September 2025
30 September 2025
The key asset in this acquisition is Merus' EGFRxLGR5 bispecific antibody, petosemtamab, currently in Phase III development.
Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population.
Lecanemab has secured approvals in 50 countries and is under review in 10 others.
New research conducted by Verizon Frontline shows that innovative technology, including drones, will be an increasingly important part of public safety work.
Jeff Miglicco, CEO & Co-Founder of PureWay highlights that dangers of medical waste's role in counterfeit weight-loss injectables.
The investment aims to scale up the production of drugs at the company’s Juncos’ biologics production facility.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
